What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
23/5 22:48
Key PointsProsight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter....